Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.

Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, van Ree JW, Knottnerus JA.

BMJ. 1999 Oct 9;319(7215):958-64.

2.

Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation: the PATAF trial study design.

Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens TG, van Ree JW, Knottnerus JA.

Control Clin Trials. 1999 Aug;20(4):386-93.

PMID:
10440565
3.

Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269].

Mant JW, Richards SH, Hobbs FD, Fitzmaurice D, Lip GY, Murray E, Banting M, Fletcher K, Rahman J, Allan T, Raftery J, Bryan S; Midlands Research Consortium of General Practice.

BMC Cardiovasc Disord. 2003 Aug 26;3:9. Epub 2003 Aug 26.

5.

Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).

Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentre F, Pousset F, Lacomblez L, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud P; FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané) Investigators.

Cerebrovasc Dis. 2001;12(3):245-52.

PMID:
11641591
6.

[Oral anticoagulation for prevention of thromboembolism in non-rheumatic atrial fibrillation: indications, effectiveness and risk].

Kottkamp H, Willems S, Hindricks G, Chen X, Haverkamp W, Hasfeld M, Borggrefe M, Breithardt G.

Z Kardiol. 1993 Nov;82(11):667-73. Review. German.

PMID:
8291287
8.
9.
10.
11.

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA investigators; Midland Research Practices Network (MidReC).

Lancet. 2007 Aug 11;370(9586):493-503.

PMID:
17693178
12.

Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.

ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A.

Lancet Neurol. 2007 Feb;6(2):115-24.

PMID:
17239798
13.

Is treatment of atrial fibrillation in primary care based on thromboembolic risk assessment?

Rutten FH, Hak E, Stalman WA, Verheij TJ, Hoes AW.

Fam Pract. 2003 Feb;20(1):16-21.

14.

Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.

Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A, Mataix L; NASPEAF Investigators.

J Am Coll Cardiol. 2004 Oct 19;44(8):1557-66.

15.

Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study.

Tsivgoulis G, Spengos K, Zakopoulos N, Manios E, Peppes V, Vemmos K.

Age Ageing. 2005 Jan;34(1):35-40.

16.

Treating the non-electrical risks of atrial fibrillation.

Gershlick AH.

Eur Heart J. 1997 May;18 Suppl C:C19-26. Review.

PMID:
9152671
17.

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M; AFFIRM Investigators.

Am Heart J. 2005 Apr;149(4):650-6.

PMID:
15990748
18.

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ.

Stroke. 2008 May;39(5):1482-6. doi: 10.1161/STROKEAHA.107.500199. Epub 2008 Mar 6.

19.

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

[No authors listed]

Arch Intern Med. 1994 Jul 11;154(13):1449-57. Erratum in: Arch Intern Med 1994 Oct 10;154(19):2254.

PMID:
8018000
20.

[Prevention of embolisms in atrial fibrillation: anticoagulation and antiplatelet therapy].

Kienast J.

Z Kardiol. 1994;83 Suppl 5:49-58. Review. German.

PMID:
7846945
Items per page

Supplemental Content

Write to the Help Desk